Sandra Hervas Stubbs-rekin lankidetzan egindako argitalpenak (9)

2022

  1. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

2021

  1. Adenovirus-mediated inducible expression of a pd-l1 blocking antibody in combination with macrophage depletion improves survival in a mouse model of peritoneal carcinomatosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Long-term systemic expression of a novel pd-1 blocking nanobody from an aav vector provides antitumor activity without toxicity

    Biomedicines, Vol. 8, Núm. 12, pp. 1-19

2019

  1. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905

2015

  1. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2013

  1. Eradication of liver-implanted tumors by semliki forest virus expressing IL-12 requires efficient long-term immune responses

    Journal of Immunology, Vol. 190, Núm. 6, pp. 2994-3004

2012

  1. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic semliki forest virus encoding IL-12

    Molecular Therapy, Vol. 20, Núm. 9, pp. 1664-1675

2011

  1. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

2010

  1. Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates

    Molecular Therapy, Vol. 18, Núm. 4, pp. 754-765